JP2009501801A5 - - Google Patents

Download PDF

Info

Publication number
JP2009501801A5
JP2009501801A5 JP2008522937A JP2008522937A JP2009501801A5 JP 2009501801 A5 JP2009501801 A5 JP 2009501801A5 JP 2008522937 A JP2008522937 A JP 2008522937A JP 2008522937 A JP2008522937 A JP 2008522937A JP 2009501801 A5 JP2009501801 A5 JP 2009501801A5
Authority
JP
Japan
Prior art keywords
dosage form
ibuprofen
famotidine
oral dosage
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008522937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009501801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/028075 external-priority patent/WO2007012019A2/en
Publication of JP2009501801A publication Critical patent/JP2009501801A/ja
Publication of JP2009501801A5 publication Critical patent/JP2009501801A5/ja
Pending legal-status Critical Current

Links

JP2008522937A 2005-07-18 2006-07-18 イブプロフェンとファモチジンとを含有する医薬およびその投与 Pending JP2009501801A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70048105P 2005-07-18 2005-07-18
PCT/US2006/028075 WO2007012019A2 (en) 2005-07-18 2006-07-18 Medicaments containing famotidine and ibuprofen and administration of same

Publications (2)

Publication Number Publication Date
JP2009501801A JP2009501801A (ja) 2009-01-22
JP2009501801A5 true JP2009501801A5 (enExample) 2009-08-27

Family

ID=37669550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008522937A Pending JP2009501801A (ja) 2005-07-18 2006-07-18 イブプロフェンとファモチジンとを含有する医薬およびその投与

Country Status (8)

Country Link
US (3) US20070043096A1 (enExample)
EP (1) EP1919288A4 (enExample)
JP (1) JP2009501801A (enExample)
CN (1) CN101257800B (enExample)
CA (1) CA2615496C (enExample)
IL (1) IL188732A (enExample)
NZ (1) NZ565846A (enExample)
WO (2) WO2007012022A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3516632B2 (ja) 2000-04-27 2004-04-05 オリジン電気株式会社 光ディスク基板の貼り合わせ方法及び装置
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
BRPI0714937A2 (pt) * 2006-07-18 2013-03-26 Horizon Therapeutics Inc forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria
US20150224056A1 (en) * 2006-07-18 2015-08-13 Horizon Pharma Usa, Inc. Pharmaceutical compositions of ibuprofen and famotidine
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008027963A2 (en) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
EP3090739A1 (en) 2008-01-04 2016-11-09 Schabar Research Associates LLC Compositions composed of naproxen sodium and nizatidine
US9629809B2 (en) 2008-07-21 2017-04-25 Si Group, Inc. High content sodium ibuprofen granules, their preparation and their use in preparing non-effervescent solid dosage forms
BRPI0916344A2 (pt) 2008-07-21 2020-07-21 Albemarle Corporation grânulos com alto teor de ibuprofeno de sódio, preparação e utilização para preparação de formas de dosagem sólidas não efervescentes
EP2588088A4 (en) * 2010-07-02 2014-05-07 Fmc Corp Inc SOLID SHAPES
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
CN102247371A (zh) * 2011-08-19 2011-11-23 北京阜康仁生物制药科技有限公司 一种以布洛芬和拉呋替丁为活性成分的药物组合物
CN103083314A (zh) * 2011-10-28 2013-05-08 四川大学 具有胃肠道保护作用的复方布洛芬
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
HK1258284A1 (zh) * 2015-10-30 2019-11-08 癌症预防制药股份有限公司 依氟鸟氨酸和舒林酸,固定剂量的组合制剂
IL268683B2 (en) 2017-02-17 2023-04-01 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
EP4647068A2 (en) * 2018-08-17 2025-11-12 Eidos Therapeutics, Inc. Formulations of ag10
CA3159988C (en) 2020-07-15 2023-09-19 Bernard Schachtel Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
BR112023019653A2 (pt) * 2021-03-24 2023-10-31 Johnson & Johnson Consumer Inc Partícula de famotidina revestida
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
HU196775B (en) * 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
DE69111287T2 (de) * 1990-04-18 1995-12-21 Asahi Chemical Ind Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung.
SK279279B6 (sk) * 1991-05-13 1998-09-09 The Boots Company Plc S(-)-nátrium-2-(4-izobutylfenyl)propionát-dihydrát
DE69228738D1 (de) * 1991-12-06 1999-04-29 Glaxo Group Ltd Zusammensetzungen zur Behandlung von entzündlichen Zuständen oder Analgesie, die Ranitidin Wismuth Citrat und einen NSAID enthalten
EP0663839A4 (en) * 1992-09-29 1998-06-03 Merck & Co Inc Ibuprofen-h 2? antagonist combinations.
ATE180668T1 (de) * 1992-12-01 1999-06-15 Spirig Ag S(+)-ibuprofen enthaltende arzneimittel
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
DE19509805A1 (de) * 1995-03-21 1996-09-26 Basf Ag Transparente, schnell freisetzende Zubereitungen von nichtsteroidalen Analgetica
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
WO1998004279A1 (en) * 1996-07-30 1998-02-05 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
FR2785539B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Particules enrobees d'ibuprofene cristallin granule
AU772188B2 (en) * 1998-11-17 2004-04-08 Nitromed, Inc. Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
HUP0301333A3 (en) * 1999-12-06 2005-06-28 Penwest Pharmaceuticals Co Sea Pharmaceutical superdisintegrant, process for its preparation and its use
AU2002305758B2 (en) * 2001-06-01 2006-09-07 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
EP1601644B1 (en) * 2003-03-05 2009-05-27 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
US20050053655A1 (en) * 2003-09-05 2005-03-10 Pharmaceutical Industry Technology And Development Center Rapid disintegrating tablets (RDTs) for pharmaceutical use and method for preparing the same
EP1691789B1 (en) * 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
WO2005076987A2 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
CA2511158A1 (en) * 2005-06-29 2006-12-29 Medical Futures Inc. Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against nsaid gastropathy
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen

Similar Documents

Publication Publication Date Title
JP2009501801A5 (enExample)
RU2011110765A (ru) Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP3806427B2 (ja) 新規鎮痛剤
JP5970189B2 (ja) 医薬調製物
JP2018507243A5 (enExample)
JP2016164165A5 (enExample)
JP2010522240A (ja) 炎症を処置するための組成物および方法
JP2013541583A5 (enExample)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
JPS6388122A (ja) 吸収および作用が速やかなサリンダツクまたはサリンダツクナトリウムと塩基の併用剤
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
JP2005528430A5 (enExample)
JP2020500864A5 (enExample)
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
JP5542309B2 (ja) 経口医薬組成物
RU2487707C2 (ru) Применение парацетамола и ибупрофена в лечении
JP5828609B2 (ja) 持続性解熱鎮痛消炎剤
JP2012505830A5 (enExample)
Zarafonetis Treatment of scleroderma
JP2016505050A5 (enExample)
JP5712249B2 (ja) ロキソプロフェン含有経口用組成物
CN104740112A (zh) 番茄红素和葡萄籽组合物在制备治疗关节炎药物中的应用
JP2019529559A5 (enExample)